Qiagen NV at Barclays Global Healthcare Conference (Virtual) Transcript
All right. Hi, everybody. Luke Sergott from Barclays. I cover life science tools diagnostics here. It is almost my true pleasure to have John Gilardi from QIAGEN with us. He seems to have mailed me all the weight he has lost.
So with that, I'll let him kind of give an open introduction into the company and speak a little bit, and then we can dive into some questions.
Thanks, Luke. It's unfortunate that we can't be together in Miami, given that this would have been your first Barclays Conference in Miami, but it's still great to see you in the new seat, and thanks for having us here.
As for QIAGEN, what I would say is that we're off to a strong start in 2021. You saw us end 2020, exceeding the goals that we had set for the year, driven by COVID testing demand as well as improving trends in the rest of our portfolio. We're looking for another year of strong growth in 2021, looking for 18% to 20% CER
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
